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ABSTRACT Evidence has recently accumulated suggesting that small noncoding RNAs, and particularly microRNAs, have the po-
tential to strongly affect the replication and pathogenic potential of a range of human virus species. Here, we report the use of
deep sequencing to comprehensively analyze small viral RNAs (18 to 27 nucleotides [nt]) produced during infection by influenza
A virus. Although influenza A virus differs frommost other RNA viruses in that it replicates its genome in the nucleus and is
therefore exposed to the nuclear microRNA processing factors Drosha and DGCR8, we did not observe any microRNAs encoded
by influenza virus genes. However, influenza virus infection did induce the expression of very high levels—over 100,000 copies
per cell by 8 h postinfection—of a population of 18- to 27-nt small viral leader RNAs (leRNAs) that originated from the precise
5= ends of all eight influenza virus genomic RNA (vRNA) segments. Like the vRNAs themselves, our data indicate that the leRNAs
also bear a 5=-terminal triphosphate and are therefore not capable of functioning as microRNAs. Instead, the high-level produc-
tion of leRNAsmay imply a role in another aspect of the viral life cycle, such as regulation of the switch from viral mRNA tran-
scription to genomic RNA synthesis.
IMPORTANCE Influenza A virus is an important human pathogen that has the potential to give rise to serious pandemics. Here, we
demonstrate that influenza A virus induces the expression of very high levels of small viral leader RNAs (leRNAs) within hours of
infection. These RNAs are unusual in that they bear a 5= triphosphate and originate from the very 5= ends of the eight viral
genomic RNA (vRNA) segments. Their high expressionmay imply an important role in the viral life cycle that could potentially
serve as a novel target for antiviral drugs.
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MicroRNAs (miRNAs) are small regulatory RNAs of ~22 nu-cleotides (nt) in length that are expressed by all multicellular
eukaryotes (1). The large majority of miRNAs are initially tran-
scribed as part of a long capped, polyadenylated transcript re-
ferred to as a primary miRNA (pri-miRNA) precursor, where they
form part of one arm of an internal ~80-nt stem-loop (2). This
stem-loop is recognized by the nuclear RNase III enzyme Drosha,
acting in concert with its cofactor DGCR8, leading to cleavage of
the pri-miRNA stem. This cleavage liberates an ~60-nt RNA hair-
pin bearing an ~2-nt 3= overhang, called the pre-miRNA interme-
diate. After nuclear export, the pre-miRNA encounters the cyto-
plasmic RNase III enzyme Dicer, which removes the terminal loop
of the pre-miRNA, leaving a second ~2-nt 3= overhang. One
strand of the resultant miRNA duplex intermediate is then incor-
porated into the RNA-induced silencing complex (RISC), where it
acts as a guide RNA to direct RISC to mRNA species bearing a
complementary sequence. Binding of RISC to mRNA target se-
quences results in inhibition of protein synthesis and some degree
of destabilization (1). It should be noted that both Drosha and
Dicer leave a 5= monophosphate after RNA cleavage and that this
5= phosphate is, in fact, critical for miRNA incorporation into
RISC (1, 3, 4).
It has recently become increasingly clear that miRNAs can ex-
ert a major positive or negative effect on viral replication (5). In
particular, it has now been demonstrated that a number of nuclear
DNA viruses carry genes that encode miRNAs that appear likely to
play an important role in promoting viral pathogenesis (6–13). In
contrast, analysis of a range of RNA viruses has failed to identify
any miRNAs encoded by viral genes (9, 14, 42). At least two rea-
sons for the current lack of RNA virus-derived miRNAs are ap-
parent. On the one hand, excision of a viral miRNA from the
genome or antigenome of an RNA virus would result in their
cleavage and degradation, which is likely to be disadvantageous.
On the other hand, it is also true that almost all the RNA viruses
examined thus far replicate in the cytoplasm, away from the nu-
clear Drosha/DGCR8 heterodimer that initiates miRNA process-
ing. If this is the key consideration, then RNA viruses that replicate
in the nucleus, unlike RNA viruses that replicate in the cytoplasm,
might express one or more viral miRNAs in infected cells. In the
case of the retroviruses HIV-1 and human T-cell leukemia virus
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type 1 (HTLV-1), we and others have presented data arguing that
these nuclear RNA viruses do not, in fact, contain genes that en-
code any miRNAs, although this issue has remained controversial
(9, 14–16).
Another prominent RNA virus family that replicates its ge-
nome in the nucleus is the Orthomyxoviridae and, in particular,
influenza A virus. Influenza A virus is a segmented, negative-
strand RNA virus, and its polymerase complex (composed of the
PB2, PB1, and PA proteins) generates not only mRNAs but also
viral genomic RNAs (vRNAs) and plus-sense intermediates in
vRNA biogenesis, called cRNAs, during infection (17). All these
RNAs are derived from the eight vRNA segments that enter the cell
in the infecting virus particle and that then rapidly migrate into
the nucleus. We were therefore curious to determine whether in-
fluenza A virus might contain genes that encode miRNAs within
one or more of its genomic vRNA segments or in the plus-sense
viral mRNAs or cRNAs.
Using deep sequencing, we demonstrate that influenza virus
does not express any viral miRNAs but instead generates high
levels of ~18- to 27-nt small viral leader RNAs (leRNAs) that orig-
inate from the very 5= end of each of the eight vRNA segments.
These leRNAs accumulate to high levels in influenza virus-
infected cells, reaching100,000 copies per cell by 8 h postinfec-
tion (hpi), a level substantially higher than the total number of
cellular miRNAs. Moreover, leRNAs differ from miRNAs both in
their relatively heterogeneous lengths and, more importantly, in
the fact that they retain a 5= triphosphate, which precludes their
incorporation into RISC (1, 3, 4). The high level of expression of
the leRNAs is consistent with their playing an important role in
the influenza virus life cycle.
RESULTS
To determine whether influenza A virus expresses miRNAs or
other small viral RNAs in infected cells, we infected the highly
permissive Madin-Darby canine kidney (MDCK) cell line at a
multiplicity of infection (MOI) of 2 per cell with the human H3N2
influenza virus isolate A/Wuhan/359/95 (18). To minimize cyto-
pathic effects, which could induce the production of cellular RNA
breakdown products, we chose to harvest total cellular RNA at 8
hpi, by which point the viral titer has plateaued, yet no cytopathic
effect was apparent (18). As our initial focus was on miRNAs
potentially encoded by viral genes, we used a previously described
cDNA synthesis protocol that directly ligates 3= and then 5= adapt-
ers onto small (~18- to 30-nt) RNAs purified from the total RNA
pool (9, 13). As a result, this cDNA synthesis protocol is depen-
dent on the presence of a 5= phosphate, which is typical of
miRNAs, but excludes RNAs bearing other 5= modifications, such
as a triphosphate or a cap.
This initial effort resulted in 135,408 usable Solexa sequence
reads of 18 to 27 nt in length, of which the majority (~79%) were
known cellular miRNAs that are conserved in humans and other
mammalian species, including canines (Table 1). This number
likely underestimates the number of cellular miRNAs, as canine
miRNAs have not yet been well characterized. In addition, we also
recovered 654 sequence reads (~0.5%) that were of influenza virus
origin. Interestingly, the large majority of these reads (550 of 654,
or ~0.4% of the total reads obtained) originated from the exact 5=
end, or very near the 5= end, of each of the eight influenza virus
vRNA segments. To further examine whether this represented a
discrete population of viral small RNAs, we next performed a
Northern blot analysis using a mixture of four oligonucleotide
probes specific for the 5= ends of the PB1, M, NA, and NP vRNA
segments. This experiment (Fig. 1) resulted in the detection of a
very strong RNA signal in the 20- to 30-nt range in influenza
virus-infected MDCK cells that was not present in uninfected
cells.
A highly expressed population of influenza virus leader
RNAs. The cDNA synthesis protocol used to generate the first
small RNA sequence library from influenza virus-infected cells is
not able to capture RNAs bearing 5= triphosphates, so the fact that
the majority of the influenza virus RNAs recovered were derived
from the 5= ends of the influenza vRNA segments, which bear a
terminal triphosphate (17), was unexpected. Moreover, given the
low level of recovery of these leRNAs,0.5% of the total number
of small RNAs sequenced, the intensity of the signal detected by
Northern analysis for these same leRNAs was also not anticipated
(Fig. 1). We therefore reasoned that there might be a high level of
expression of viral small RNAs originating from the 5= ends of the
eight vRNAs in influenza virus-infected cells that was not cap-
TABLE 1 Characterization of two influenza virus-infected small RNA
cDNA libraries
Characteristic Value (%) for characteristic
Library 1a Library 2b
Total no. of reads 135,408 5,365,655
No. of influenza readsc 654 (~0.5) 1,792,020 (~33)
No. of cellular miRNAsd 107,106 (~79) 1,029,813 (~19)
No. of other readse 27,648 (~20) 2,543,822 (~47)
a Library 1 utilized a cDNA synthesis protocol that captures only small (18- to 27-nt)
RNAs bearing a 5= monophosphate.
b Library 2 used the same total RNA preparation but utilized a cDNA synthesis protocol
that captures small RNAs regardless of their 5= phosphorylation status.
c Influenza reads are reads that map anywhere on the influenza virus genome.
d Cellular miRNAs refers to reads that are homologous to known human miRNAs
(miRBase version 15.0).
e “Other reads” refers to reads that represent mRNA, rRNA, etc., breakdown products
or that could not be assigned.
FIG 1 Northern blot analysis of influenza virus leader RNA expression. Total
RNA was isolated 8 hpi from MDCK cells infected with the H3N2 influenza
virus isolate A/Wuhan/359/95 and analyzed using a pool of oligonucleotide
probes designed to recognize the 5= 18 nt of the PB1, NA, M, and NP vRNAs.
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tured in our initial deep sequencing effort, as the library used
would contain only rare 5=-terminal influenza vRNA fragments
that had undergone partial hydrolysis in the cells, or during RNA
isolation, to leave a 5= monophosphate.
To address this issue, we therefore generated a second small
RNA library, using the same influenza virus-infected cell total
RNA preparation, that included a step whereby all 5= phosphates
were first removed by incubation with alkaline phosphatase, fol-
lowed by addition of a single 5= phosphate using polynucleotide
kinase (PNK). The advantage of this modified technique is that it
would allow us to recover any viral RNAs bearing a 5= triphos-
phate in this second cDNA library. The disadvantage is that we
would also recover common RNA breakdown products lacking
any 5= phosphate moieties.
Solexa deep sequencing of this second small RNA library
yielded 5,365,655 usable reads of 18 to 27 nt in length (Table 1). Of
these, 2,543,822 (~47%) represented RNA breakdown products
(cellular mRNA, rRNA, tRNA, snRNA, etc.) or were not assign-
able, a substantially higher percentage than seen with library 1
(Table 1). On the other hand, we recovered only 1,029,813 iden-
tifiable canine cellular miRNA reads in library 2, which repre-
sented ~19% of the total number of reads, far less than the ~79%
seen in library 1. Most strikingly, the number of influenza virus
reads increased from ~0.5% (654) to ~33% (1,792,020) of the
total number of reads. Analysis of the genomic origin of these viral
small RNAs revealed that, overall, 98.4% coincided with the pre-
cise 5= end of each of the eight vRNA segments, varying from a low
of 97.3% in the case of the PB2 vRNA to a high of 99.6% for the NA
segment (Table 2). In terms of segment origin, we recovered a low
of 63,435 leRNAs derived from the NS segment to a high of
562,102 derived from PB2 (Table 2). By analogy to the small,
5=-triphosphorylated viral leader RNAs that have been reported in
cells infected by other negative-strand RNA viruses (19–23), we
refer to influenza virus small RNAs that originate from the 5= ends
of the vRNA segments as influenza virus leader RNAs (leRNAs).
Analysis of the size distribution of the 18- to 27-nt cellular
small RNAs in library 2 (Fig. 2A) revealed that the total cellular
small RNA population, which represents a mixture of RNA break-
down products and cellular miRNAs, was heterogeneous in length
but with a clear peak at the predicted 22- or 23-nt size expected for
miRNAs (1), even though miRNAs appear to represent only a
small proportion of these cellular RNA sequences (Table 1). (The
peak at 23 nt reflects the very high level of expression of a 23-nt
isoform of miR-21 in MDCK cells.) In contrast, the influenza virus
leRNAs showed no clear size preference, although 19-nt, 21-nt,
and 22-nt species were slightly predominant (Fig. 2B). Further
breakdown of the leRNA size distribution by viral segment of or-
igin (Table 3) again showed no particular size preference, with the
most common size varying from 19 nt (PB2, M, NS, and HA) to
25 nt (PB1), with substantial numbers recovered at all sizes be-
tween the 18-nt and 27-nt cutoffs. (Due to technical limitations
intrinsic to the Solexa sequencing protocol, RNAs of28 nt in size
could not be unequivocally identified.) The absence of tight clus-
tering of the leRNAs at the 22/23-nt size characteristic of miRNAs
is expected, as our data strongly suggest that the leRNAs contain a
5=-terminal triphosphate, which would preclude incorporation
into RISC.
We also recovered a small number of influenza virus RNA
fragments (28,292) that originate from regions of the influenza
virus genome other than the 5= ends of vRNAs. Could these rep-
resent viral miRNAs? In fact, analysis of their size distribution
again revealed no preference for the 22/23-nt size characteristic of
miRNAs (Fig. 2C). Analysis of the precise origin of all small influ-
TABLE 2 Percentage of leader RNAs compared to all influenza virus-
derived sequencesa
Gene No. of influenza virus RNAs No. of leRNAs % of leRNAs
PB2 577,849 562,102 97.3
PB1 195,040 192,073 98.5
PA 378,204 373,593 98.8
HA 72,844 72,085 99.0
NP 283,744 282,006 99.4
NA 113,579 113,167 99.6
M 106,629 105,270 98.7
NS 64,134 63,435 98.9
Overall 1,792,020 1,763,730 98.4
a This table presents the number and percentage of small influenza virus RNAs that
start at position 1 of each vRNA segment, defined as leader RNAs (leRNAs).
FIG 2 Size distribution of small RNAs returned by Solexa/Illumina deep
sequencing. (A) Size distribution of all non-influenza virus small RNAs recov-
ered in library 2 (Table 1). (B) Size distribution of all influenza virus small
RNAs. (C) Size distribution of all non-leRNA influenza virus small RNAs.
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enza virus RNAs, including the leRNAs, within the eight genomic
segments of influenza virus (Fig. 3) revealed the expected high
level of origin from the 5= ends of the vRNA segments that is the
defining characteristic of influenza virus leRNAs and also showed
a modest enrichment of influenza virus small RNAs from near the
3= end of the vRNA, as well as from the 3= end of the mRNA/cRNA
population, although these are all present at a level that is1,000-
fold lower than the level of leRNAs. Other influenza virus-derived
small RNAs were derived from random locations within both the
vRNA and mRNA/cRNA transcripts, and not from one or a small
number of discrete sites, as would be predicted for miRNAs
(Fig. 3). Instead, this distribution suggests that these are random
viral RNA breakdown products.
Influenza virus leader RNAs are expressed early after infec-
tion. After infection by influenza virus, the eight vRNA segments
are initially copied to yield viral mRNA species that are then trans-
lated to yield viral proteins (17). These newly synthesized influ-
enza virus proteins, in particular the viral nucleoprotein NP, are
then thought to induce a partial switch from mRNA transcription
to genome replication, i.e., to cRNA synthesis followed by the
generation of new vRNAs, beginning at 1 or 2 hours after infection
(24–26). It has been proposed that these progeny vRNAs can make
a significant contribution to viral mRNA, and hence protein, syn-
thesis, although this has remained controversial (25, 27, 28).
The leRNAs we observe must be derived from transcripts cop-
ied from viral cRNAs and are likely to result from nonprocessive
transcription of the 3= ends of the cRNAs or, less probably, from
endonucleolytic cleavage of vRNA transcripts. In either case, one
might expect leRNA expression to occur somewhat later in the
viral life cycle. To address this issue, we performed a time course
analysis of leRNA production in MDCK cells infected with either
the H3N2 virus isolate A/Wuhan/359/95 (18) or an H1N1 clinical
isolate, A/HK/54/98 (29), at a multiplicity of infection (MOI) of
~2/cell (Fig. 4A and B). Interestingly, we observed that the H3N2
virus gave rise to detectable leRNA expression as soon as 2 hpi,
which increased rapidly up to 8 hpi. The pattern observed with the
more cytopathic H1N1 isolate was slightly different, with leRNA
expression being first detected at ~4 hpi and then increasing rap-
idly to 6 hpi. We also noted some differences in leRNA size, with
the H3N2 isolate giving rise to leRNAs that were essentially all
between 20 and 30 nt in size (Fig. 4A), while the H1N1 isolate gave
rise to some leRNAs that appeared to be slightly over 30 nt, al-
though leRNAs 20 to 30 nt in size again predominated (Fig. 4B).
To extend these data to a third influenza virus isolate and to a
second cell line, we harvested total RNA samples from human
293T cells infected with the H3N2 influenza virus isolate
A/Udorn/72 (30) at an MOI of ~1. The assay used to quantify
leRNA expression in this instance was quantitative reverse tran-
scriptase PCR (qRT-PCR), using a stem-loop probe specific for
the PB2 leRNA, which was expected to allow detection of the
leRNAs over a wide dynamic range. As shown in Fig. 4C, we were
again able to detect leRNAs as soon as 2 hpi, but we now observed
that the leRNAs continued to accumulate up to 36 hpi. Overall,
these data suggest that leRNAs and vRNAs are likely to arise si-
multaneously and quite early in the influenza virus life cycle and
also suggest that the leRNAs, like the full-length vRNAs, accumu-
late in infected cells and can reach high levels at late times after
infection. We note that previous reports have demonstrated that
vRNA synthesis can initiate as soon as 1 hpi (25).
DISCUSSION
The initial goal of this research project was to determine whether
influenza A virus, which copies its RNA genome in the nucleus,
might give rise to viral miRNAs. Unexpectedly, we instead ob-
served that influenza virus generates very high levels of short (18-
to 27-nt-long) viral leader RNAs (leRNAs) that originate from the
very 5= ends of all eight vRNA segments. Our data strongly suggest
that these leRNAs, like the vRNAs themselves, contain a 5=-
terminal triphosphate. As a result, the leRNAs were recovered very
inefficiently when a standard small RNA sequencing protocol,
which requires a 5= phosphate, was used. However, leRNAs be-
came the dominant small RNA species when a modified protocol
was used; the modified protocol allows the generation of cDNAs
from small RNAs regardless of the 5= phosphorylation status (Ta-
ble 1). Remarkably, under these conditions, we recovered sub-
stantially more leRNAs from cells infected 8 h previously with
influenza A virus than total cellular miRNAs. As individual cells
generally express from 80,000 to over 100,000 miRNAs (1), this
means that influenza leRNAs were expressed at well over 100,000
copies per cell by 8 hpi.
Because miRNA incorporation into RISC requires a 5= mono-
phosphate (1, 3, 4), the leRNAs we detected cannot represent
TABLE 3 Size distribution of H3N2 leader RNAsa
Length (nt) No. of leRNAs of the indicated length derived from the following influenza vRNA segment:
PB2 PB1 PA HA NP NA M NS
18 33,567 8,512 15,097 6,858b 4,498 14,251 7,049 6,858b
19 115,343 10,093 15,888 15,330b 13,470 6,462 28,056 15,330b
20 36,539 18,962 34,487 3,742b 24,710 21,361 9,064 3,742b
21 70,309 28,898 70,226 7,308b 42,140 9,728 26,498 7,308b
22 82,197 12,056 105,011 7,526 46,306 8,184 16,255 5,247
23 22,272 20,949 63,814 2,878 48,082 15,643 11,174 6,664
24 42,376 16,307 26,101 5,006 42,786 14,607 1,500 2,296
25 32,327 34,429 24,996 14,640 42,608 15,033 2,002 7,152
26 75,262 32,694 8,399 5,673 12,353 3,100 3,346 5,094
27 51,910 9,173 9,574 3,125 5,053 4,798 326 3,745
Total 562,102 192,073 373,593 72,085 282,006 113,167 105,270 63,435
a This table presents the size distribution, in nucleotides, of the leRNAs derived from each of the indicated influenza vRNA segments, with the most prevalent size in boldface type.
b Because the HA and NS vRNAs are identical in sequence through nucleotide 21, we could not assign reads derived from these sequences unequivocally. We have therefore
arbitrarily assigned 50% of the reads to each of these two segments.
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miRNAs. Moreover, because both Dicer and Drosha cleavage
leaves behind a 5= monophosphate (1), these RNase III enzymes
are clearly not involved in leRNA biogenesis. Most probably, the
leRNAs result from premature termination by the viral RNA-
dependent RNA polymerase (RdRP) while utilizing a cRNA tem-
plate. While this has been previously reported to occur at high
FIG 3 Genomic origin of all influenza virus small RNAs. Small red circles indicate the frequency and genomic locations of the starting nucleotide of
vRNA-derived sequences recovered by deep sequencing, while small green circles represent the frequency and genomic locations of mRNA/cRNA-derived
sequences for all eight influenza virus genome segments. The viral leRNAs, which start at nucleotide 1 of the vRNA, are indicated by a large red circle containing
a small red circle. The data used were derived from cDNA library 2 (Table 1). All sequences are aligned on the basis of their 5= ends, which are aligned to the left
for the vRNAs and to the right for the viral cRNAs/mRNAs. The frequency is the number of viral sequence reads obtained that bear identical 5= ends.
Influenza Small Viral Leader RNAs
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levels in vitro (31), it also remains formally possible that the
leRNAs instead arise from endonucleolytic cleavage of nascent or
mature vRNA molecules. The heterogeneous 3= ends of the
leRNAs (Table 3) would appear to make the latter hypothesis less
likely.
While leRNAs account for 98.4% of all small influenza viral
RNAs, we did detect small RNAs that were derived from regions
other than the precise 5= ends of the vRNAs. However, these in-
fluenza virus small RNAs did not show a discrete size of ~22 nt, as
predicted for both miRNAs and small interfering RNAs (siRNAs)
(Fig. 2C) (1), and are therefore likely RNA breakdown products.
Consistent with this hypothesis, these small viral RNAs were not
derived from discrete locations within the influenza virus
genomic segments, as would be expected for viral miRNAs
(Fig. 3).
It is interesting to compare our observations with previously
published work documenting the expression of short leader
RNAs, derived from the 5= ends of the genomic RNA, in cells
infected with a range of other negative-strand RNA viruses, in-
cluding vesicular stomatitis virus (VSV) (21, 23), rabies virus (22),
and respiratory syncytial virus (19). The most studied of these are
the VSV leRNAs, which contain a 5=-terminal triphosphate, range
from ~44 to ~54 nt in length, and have been reported to be ex-
pressed at ~300 copies per infected cell (20, 32, 33). Despite their
very low level of expression, the VSV leRNAs have been proposed
to play a key role in the VSV life cycle by regulating the switch from
mRNA transcription to genomic RNA replication by binding to
the VSV nucleocapsid protein (20). The VSV leRNAs have also
been shown to bind the cellular protein La (33, 34), which may
prevent activation of the cellular innate immunity factor RIG-I by
these 5=-triphosphorylated RNA molecules (19).
While this article was being prepared, Perez et al. (35) reported
the expression of analogous influenza virus leader RNAs, which
they termed small viral RNAs, in a range of influenza virus-
infected cell types, including human lung epithelial cells and em-
bryonated chicken eggs. These small viral RNAs were initially de-
tected by conventional deep sequencing, using a protocol that
captures only small RNAs bearing a 5= monophosphate, and as a
result, the small viral RNAs comprised only 1,524 (0.04%) of the
total of 4,217,121 short RNA sequence reads reported by this
group. This is comparable to, but even lower than, the ~0.4% of
total sequence reads contributed by the leRNAs when we used a
comparable sequencing protocol and contrasts with the very high
level of leRNAs that were detected when a protocol that captures
5=-triphosphorylated short RNAs was used (Table 1).
Perez et al. (35) reported that their influenza virus small RNAs
were between 22 and 27 nt in length and were derived from the 5=
ends of all eight influenza virus genome segments, which is similar
to what we have observed for the leRNAs (Fig. 2B and Table 3),
although it is also clear that the leRNAs bear fairly heterogeneous
3= ends. Our data do differ somewhat from Perez et al. (35) in that
these authors reported that their small viral RNAs were detectable
starting at ~12 hpi, while we could clearly see leRNA expression at
6 hpi and sometimes even earlier (Fig. 4). Indeed, by 8 hpi, leRNAs
were found to be expressed at105 copies per cell, as noted above.
This discrepancy may result from the use of different cell types in
these analyses, as Perez et al. (35) primarily used A549 cells, while
we primarily used MDCK cells.
An important observation reported by Perez et al. (35) is that
introduction of an antisense locked nucleic acid (LNA) oligonu-
cleotide (36) complementary to the HA segment leRNA inhibits
HA vRNA synthesis yet had little or no effect on HA mRNA or
cRNA transcription, thus suggesting that leRNAs might play a
critical role in virus genome replication, perhaps by triggering the
switch from mRNA transcription to genome replication. This re-
sult is perhaps unexpected, as it has previously been proposed that
production of optimal levels of influenza virus mRNAs, and hence
proteins, requires mRNAs generated by transcription of newly
generated vRNAs, not just mRNAs transcribed from the input
virus vRNA genomes (25, 28, 31). If this hypothesis is indeed
correct, then loss of leRNA function should inhibit not only
vRNA, but also mRNA, synthesis, which was not observed (35).
We note that the LNA used in this experiment has the potential to
anneal to not only the HA leRNAs but also to the identical vRNA
5= ends present on both the input and newly generated HA vRNA
segments. Given data showing that the 5= 13 nt or so of the vRNAs
plays a critical role in influenza virus transcription (17, 37), it may
be difficult to segregate phenotypic effects resulting from LNA
annealing to the viral leRNAs from effects resulting from LNA
annealing to the vRNAs themselves. Nevertheless, the hypothesis
that the influenza virus leRNAs play a critical role in the temporal
regulation of influenza virus RNA synthesis (35) is an important
one and certainly consistent with their very high level of expres-
sion. Moreover, the proposed role for leRNAs in the influenza
virus replication cycle is similar to that proposed for the viral
FIG 4 Time course analysis of influenza virus leader RNA expression. (A)
Northern analysis of RNA samples isolated from MDCK cells infected with
H3N2 isolate A/Wuhan/359/95 and harvested at the indicated time points,
given as hours postinfection (hpi) above the lanes. This Northern blot was
analyzed using the same leRNA-specific probes used in Fig. 1. (B) Expression
of H1N1 isolate A/HK/54/98-derived leRNAs in infected MDCK cells at the
indicated times postinfection. In panels A and B, the migration positions of
small RNA size markers are indicated to the right of the blots, and U6 RNA
served as a loading control. (C) qRT-PCR analysis of influenza virus leRNA
expression in 293T cells infected with the influenza virus isolate A/Udorn/72.
Samples were harvested at the indicated time points, given as hpi. The qRT-
PCR probe used is specific for leRNAs derived from the PB2 RNA segment.
Data are given as a multiple of the qRT-PCR signal obtained using mock-
infected cells, which was set at 1.
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leader RNAs encoded by VSV, which may play an equivalent role
in activating VSV genomic RNA replication (20). On the other
hand, it is also possible that the leRNAs simply represent pre-
maturely terminated vRNA transcripts and, therefore, do not reg-
ulate vRNA synthesis. On the basis of previous data obtained us-
ing other negative-strand RNA viruses, one could also envision
leRNAs playing a role in vRNA encapsidation into newly gener-
ated progeny virions (38) or in regulating innate immune re-
sponses (19, 22, 33, 34). In any case, the high level of expression of
viral leRNAs in influenza A virus-infected cells does suggest an
important role(s) in the virus replication cycle that could repre-
sent a novel target for the treatment of influenza virus-induced
disease.
MATERIALS AND METHODS
Cell culture, infections, andRNA isolation.Madin-Darby canine kidney
(MDCK) cells were maintained in Eagle’s minimum essential medium
supplemented with 10% fetal bovine serum, nonessential amino acids,
and sodium pyruvate. Cells were infected with influenza virus at an MOI
of 2 and harvested at the indicated time points. Total RNA was harvested
using TriReagent according to the manufacturer’s protocol.
Solexa/Illumina deep sequencing. cDNA libraries for deep sequenc-
ing were prepared from total RNA samples as previously described (9, 13).
Briefly, small RNAs 18 to 30 nt in length were isolated from ~30g of total
RNA by gel fractionation and then sequentially ligated to 3= and 5= linkers.
cDNA libraries for deep sequencing were then generated by standard re-
verse transcription and PCR amplification of the ligated small RNAs. Data
were returned in FASTA format and analyzed using custom scripts in
addition to the formatdb, megablast, blastoutparse, and filter alignment
scripts of the miRDeep software package (39). To capture all small RNAs,
regardless of their 5= phosphorylation status, additional dephosphoryla-
tion and kinasing steps were included following the 3= linker ligation, just
prior to ligation of the 5= linker. Specifically, gel-purified 3= linker-ligated
RNAs were dephosphorylated in a 20-l reaction mixture with 20 U of
alkaline phosphatase at 37°C for 1 h. Dephosphorylated RNAs were puri-
fied by precipitation, and 5= monophosphates were added in a 20-l re-
action mixture with 10 U of T4 PNK and an excess of ATP at 37°C for 1 h.
All other aspects of sample preparation were identical to the standard
protocol (9, 13).
Northern blot analysis. leRNA expression was analyzed by standard
small RNA Northern blot analysis as previously described (6, 7). Briefly,
30 g of total RNA was loaded onto 15% Tris-borate-EDTA (TBE)-urea
gels. RNAs were transferred onto nitrocellulose and fixed by UV cross-
linking. The top portion of the blots, which contain the large viral RNAs,
were then removed to avoid titration of the pool of end-labeled probes
recognizing the PB1 (5=-AAAATGCCTTGTTTCTACT-3=), NA (5=-
AAACTCCTTGTTTCTACT-3=), M (5=-AACTACCTTGTTTCTACT-
3=), and NP (5=-AAATACCCTTGTTTCTACT-3=) leRNAs.
Quantitation of leRNA synthesis using qRT-PCR. Custom TaqMan
stem-loop primers from Applied Biosystems were designed against the
most common isoform of the PB2 leRNA recovered from deep sequenc-
ing (5=-AGUAGAAACAAGGUCGUUU-3=) and used to analyze RNA
harvested from influenza virus-infected cells, as previously described (40).
Briefly, 10 ng of total RNA was used as a template for reverse transcription.
The sample was then diluted to 60 l, of which 8 l was used for PCR.
Values were normalized to a cellular miRNA, miR-16, and displayed as
fold expression relative to a mock-infected sample, as previously de-
scribed (41).
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